Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05732103 · ClinicalTrials.gov registry record · Phase 1
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Chordia Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 225
- Enrollment target
- 7
- Study locations
NCT05732103 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by Chordia Therapeutics. The registered enrollment target is 225 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (96% higher). The trial reports 7 study locations across 7 states.
The verdict
NCT05732103, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Chordia Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 225 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS), or MDS/MPN (including CMML). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (RP2D) for further clinical development. This is followed by initial expansion cohorts in AML and/or HR-MDS where patients will be treated with CTX-712 at the RP2D to gain further confidence in the selected dose level. Additional expansion cohorts may be initiated if considered necessary. After RP2D is determined, Drug-Drug-Interaction cohorts will be started. The phase 2 part of the study will commence after the RP2D has been identified and confirmed and will evaluate therapeutic activity in R/R AML or R/R HR-MDS, in addition to confirmation of the safety profile.
Conditions Studied
Interventions
- DRUG CTX-712
Study Locations (7)
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Mayo Clinic Florida - Jacksonville
Minnesota
- Mayo Clinic Comprehensive Cancer Center - Rochester
New York
- The University of Rochester - Rochester
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Virginia
- University of Virginia - Charlottesville
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05732103
The ClinicalTrials.gov registry entry for NCT05732103 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (96% higher). The listed sponsor is Chordia Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which CTX-712 is the first listed.
NCT05732103 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05732103 about?
NCT05732103 is a clinical study titled "A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes". The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syn...
What is the current status of trial NCT05732103?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2023-04-25. Estimated completion is 2029-02.
What conditions does trial NCT05732103 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes.
What interventions are being tested in trial NCT05732103?
The interventions under investigation include: CTX-712 (DRUG).
Who is sponsoring clinical trial NCT05732103?
This trial is sponsored by Chordia Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05732103 being conducted?
This trial has 7 study locations across Arizona, Florida, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.